Skip to content
Screener

BioCryst Pharmaceuticals BCRX Other Income (Expense)

Other Income (Expense) at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$987K+868%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$60.6M+7.1%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$119K-77.2%
Precigen logo
PrecigenPGEN
-$1.94M+93.9%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1M-50.0%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$18.21M-55.0%

Segments

By segment

See full
Reportable Segment$27K+143%

Other financials

Income statement

See full
Revenue$218.3M+33.6%
Gross profit$214.4M+33.5%
Operating income$98.5M+231%
Net income$78.4M+1,442%
EPS (diluted)$0.30+1,400%

Balance sheet

See full
Cash & equivalents$156.4M+73.9%
Total debt$410.9M+59.9%
Total equity-$454.3M-7.8%
Total assets$557.9M+22.0%

Cash flow

See full
Operating cash flow$104.3M+153%
CapEx$209.0K+16.8%
Free cash flow$104.1M+153%

Valuation

See full
Market cap$2.38B+31.6%
Enterprise value$2.63B+33.4%
P/S2.5×-0.7×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-33.3%-43.0pp
Net margin-40.9%-50.2pp
FCF margin39.7%

Returns & leverage

See full
Return on equity-882.8%
Debt / equity0.1×
Current ratio2.3×+0.1×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.

The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:04 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053300
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Foreign currency gains (losses), net27(63)(198)(62)
Loss on extinguishment of debt(4,171)(4,171)
Other income (expense), net260(1,202)
Total other expense, net(18,991)(23,300)(38,201)(43,769)
Income (loss) before income taxes79,4746,486(641,334)7,244
Income tax expense1,0791,4012,0832,127
Net income (loss)$78,395$5,085$(643,417)$5,117
Other comprehensive (loss) income:

Item 1. Financial Statements (Unaudited):

FAQ

What is BioCryst Pharmaceuticals's other income (expense)?
BioCryst Pharmaceuticals (BCRX) reported other income (expense) of -$18.99M in Q2 2026.
How has BioCryst Pharmaceuticals's other income (expense) changed year-over-year?
BioCryst Pharmaceuticals's other income (expense) increased by 18.5% year-over-year, from -$23.3M to -$18.99M.
What is the long-term trend for BioCryst Pharmaceuticals's other income (expense)?
Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's other income (expense) has grown at a 178.9% compound annual growth rate (CAGR), from $1.22M to -$73.6M.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.

Ask your AI about BioCryst Pharmaceuticals's other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude